Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

Leukemia Research

Volumn 26, Issue 8, 2002, Pages 757-763

  Liu, Yongqing ^a   Zhang, Weidong ^a   Chan, Tim ^a   Saxena, Anurag ^a   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Antitumor immunity; Cell fusion; Dendritic cells; Engineered tumor cells; IL 4

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CYTOKINE; DNA VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; MACROGOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUSION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC ENGINEERING; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HYBRIDOMAS; IMMUNITY; INTERLEUKIN-4; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0036286494     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00002-4     Document Type: Article

References (37)

1. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
2. The transporters associated with antigen presentation
3. Cell biology of antigen processing and presentation to MHC class I molecule restricted T lymphocytes
4. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4
5. A functional defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer
6. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity
7. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukine-4, interleukin-7, tumor necrosis factor and interferon gamma
8. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1α-expressing tumor: Linkage between inflammation and specific immunity
9. Role of bone marrow-derived cells in presenting MHC class I restricted tumor antigens
10. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptide elicit protective and therapeutic antitumor immunity
11. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
14. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells
15. Induction of antitumor activity by immunization with fusion of dendritic and carcinoma cells
16. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
17. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
18. Improved methods for the genration of dendritic cells from nonproliferating progenitors in human blood
19. Histamine induces CD86 expression and chemokine production by human immature dendritic cells
20. Dendritic cells genetically modified with adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
21. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo
22. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1
23. Transfection of immature murine bone marrow-derived dendritic cells with granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity
24. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
25. Regression of engineered tumor cells secreting cytokines ia related to a shift in host cytokine profile from type 2 to type 1
26. Direct activation of CD8 cytotoxic T lymphocytes by dendritic cells
27. Murine epidermal Langerhans cells as a model to study tissue dendritic cells
28. Dendritic cells and the control of immunity
29. Dendritic cells: Antigen presentation, accessory function and clinical relevance
30. Origin, maturation and antigen presenting function of dendritic cells
31. Cytokines and their effects on maturation, differentiation and migration of dendritic cells
32. Efficient antitumor immunity derived from enhanced maturation of dendritic cells which had phagocytosed apoptotic tumor cells
33. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells
34. Transforming growth factor and IL-4 cause helper T cell precursors to develop into distinct effector cells that differ in lymphokine secretion pattern and cell surface phenotype
35. IL-4 is a mediator of IL-12p70 induction by human Th2 cells: Reversal of polerized Th2 phenotype by dendritic cells
36. Genetic modification of a carcinoma with IL-4 gene increases the influx of dendritic cells relative to other cytokines
37. Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation